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images and the whole-mount histopathology section 
(r = 0.94, p = 0.018). The damage-estimation maps and 
histopathology specimen showed a correlation of r = 0.33 
(p = 0.583). On histopathology, the homogeneous necrotic 
area was surrounded by a reactive transition zone (1–5 mm) 
zone, showing neovascularisation, and an increased mitotic 
index, indicating increased tumor activity.
Conclusions The actual ablation zone was better indicated 
by T1-weighted contrast-enhanced than by damage-estima-
tion maps. Histopathology results highlight the importance 
of complete tumor ablation with a safety margin.
Keywords Prostate cancer · MRI · Focal therapy ·  
Laser ablation
Introduction
With an estimated amount of 233,000 newly diagnosed 
patients and 29,000 deaths in the United States in 2014, 
prostate cancer (PCa) has a significant impact on society 
[1]. The treatment choice for low-to-intermediate grade PCa 
patients ranges between active surveillance and whole-gland 
therapies, i.e., radical prostatectomy or radiotherapy. How-
ever, these treatments come with morbidity and influence 
quality-of-life (QoL) [2, 3]. For instance, 2 years after treat-
ment, 3.2–9.6 % of these patients experience urinary leak-
age and 56–78.8 % suffers from erectile dysfunction [2, 3].
Focal therapy is an emerging alternative treatment option 
for low-to-intermediate grade PCa [4]. It is a strategy, by 
which the overtreatment burden of the current prostate can-
cer pathway could be reduced, and QoL is preserved. The 
challenge is to treat the tumor entirely, sparing normal pros-
tate tissue, especially near the neurovascular bundles and 
the urethral sphincter, and to minimize potential morbidity. 
Abstract 
Purpose To correlate treatment effects of MRI-guided 
focal laser ablation in patients with prostate cancer with 
imaging using prostatectomy as standard of reference.
Methods This phase I study was approved by the Institu-
tional Review Board. Three weeks prior to prostatectomy, 
five patients with histopathologically proven, low/inter-
mediate grade prostate cancer underwent transrectal MRI-
guided focal laser ablation. Per patient, only one ablation 
was performed to investigate the effect of ablation on the 
tissue rather than the effectiveness of ablation. Ablation 
was continuously monitored with real-time MR tempera-
ture mapping, and damage-estimation maps were computed. 
A post-ablation high-resolution T1-weighted contrast-
enhanced sequence was acquired. Ablation volumes were 
contoured and measured on histopathology specimens (with 
a shrinkage factor of 1.15), T1-weighted contrast-enhanced 
images, and damage-estimation maps, and were compared.
Results A significant volume correlation was seen between 
the ablation zone on T1-weighted contrast-enhanced 
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Currently, focal therapy should be performed under strict 
surveillance, because of its experimental nature.
Various minimal invasive techniques, such as cryoabla-
tion, high-intensity focused ultrasound (HIFU), irrevers-
ible electroporation, and focal laser ablation (FLA), have 
been used to perform focal therapy in PCa patients [5–11]. 
All these techniques have their own characteristics and are 
still evolving. At this moment, there is no consensus which 
technique is optimal for focal therapy.
Of the available minimal invasive focal therapy tech-
niques, MRI-guided FLA is considered a promising option, 
since it is fast, creates a sharply defined ablation zone, is 
minimally invasive for the patient, and can be performed 
under local anesthesia in an outpatient setting. During this 
treatment, a laser fiber is inserted into the tumor and the 
tissue is irreversibly damaged and destroyed when its tem-
perature increases >60 °C. The total ablation process takes 
only a few minutes. Furthermore, repeat treatments, as well 
as secondary radical treatment, are still possible. MRI guid-
ance appears essential in FLA and might prove to be the 
only imaging modality for correct targeting of the index 
lesion, facilitating accurate fiber placement, real-time mon-
itoring of the ablation with the help of temperature map-
ping, and verification of complete tumor ablation [12].
To date, only a few studies reported on MRI-guided FLA 
in PCa patients [5, 13–17]. Moreover, the latter include feasi-
bility studies using small sample sizes and follow-up ≤1 year. 
One study validated the ablation volume after ultrasound-
guided FLA, but used a laser system with a different wave-
length [12]. Validation of MRI-guided FLA is required, 
before it can gain acceptance as treatment option for patients 
with low-to-intermediate grade PCa. Insight into the actual 
treatment zone can be obtained by comparing per-procedural 
MRI-temperature maps and histopathology correlation.
Therefore, the goal of our study was to correlate treat-
ment effects of MRI-guided FLA, rather than treatment 
success. Before radical prostatectomy, patients underwent 
MRI-guided FLA as extra treatment. One single abla-
tion per tumor was performed to investigate the effect of 
the ablation on the tissue, rather than the effectiveness of 
the treatment. Damage-estimation maps derived of MRI-
temperature maps, post-ablation T1-weighted contrast-
enhanced (T1wCE) MR images, and histopathology speci-
mens were used to correlate the expected and actual size of 
the ablated region.
Materials and methods
Patients
The study was approved by the Institutional Review Board 
(IRB) and all patients provided written informed consent. 
Between May 2012 and November 2013, five patients were 
included. A study flow diagram is shown in Fig. 1. Inclu-
sion criteria were men with newly diagnosed and histo-
pathologically proven PCa with a prostate-specific antigen 
(PSA) level of ≤20 ng/mL, Gleason score ≤7, stage ≤T2b, 
no previous treatment for PCa, scheduled for radical pros-
tatectomy, and a tumor lesion visible on the anatomical 
T2-weighted (T2w) and/or diffusion-weighted images 
(DWI) of the diagnostic multi-parametric MRI and located 
more than 2 cm of the neurovascular bundle. Patients with 
contra-indications to MRI or MRI-guided FLA, nodal or 
metastatic disease, or an estimated Glomerular Filtration 
Ratio <40 mL/min/1.73 m2 were excluded.
MRI‑guided focal laser ablation
Patients were prescribed antibiotic prophylaxis (ciprofloxa-
cin) for three days, starting on the day before the FLA pro-
cedure. All procedures were performed on a 3 Tesla MRI 
Paent 
included
Transrectal 
MRI-guided 
FLA
Radical 
Prostatectomy
End follow-up
3 Weeks
Fig. 1  Study flow diagram
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scanner (TrioTIM, Siemens, Erlangen, Germany) and a 
980 nm diode laser system (Visualase, Houston, Texas, 
USA). Patients were positioned head first in prone position 
on the scanner table. A pelvic phased-array coil was placed 
over the patient’s pelvis.
A gadolinium-filled needle guide was inserted in the rec-
tum and attached to an MRI-compatible device (DynaTrim, 
Invivo, Schwerin, Germany), originally developed for 
MRI-guided biopsies. The procedure was performed under 
local anaesthetic block administered by bilateral injections 
of lidocaine between the base of the prostate and the semi-
nal vesicles [18]. Anatomical T2w-images and DWI were 
acquired to re-identify the MRI visible lesion. All image 
parameters are shown in Table 1. TrueFisp images were 
acquired in two directions, to direct the needle guide to the 
lesion. After correct alignment, a 14-gauge catheter with a 
titanium trocar was inserted through the needle guide. Once 
the catheter was positioned inside the tumor, the titanium 
trocar was replaced by the laser fiber. The tip of the laser 
fiber was unsheathed from the catheter to enable immediate 
contact with the tumor tissue. Proper laser fiber placement 
was verified in two ways: first by acquiring a TrueFisp 
sequence and second by applying laser energy on a reduced 
power level. This was insufficient to cause thermal injury; 
however, this was visible on the MRI thermometry images.
The FLA procedure was continuously monitored with 
MRI thermometry images, acquired every 5 s in a single 
plane through the laser fiber. Relative temperatures were 
calculated based on the proton resonance frequency (PRF) 
method [19], and the temperature maps (Fig. 2a) were 
shown on the integrated standalone Visualase worksta-
tion connected to the MRI scanner. If the temperature at 
a certain point increased too much, this was immediately 
visible. Next to the temperature maps, a damage-estima-
tion zone with an estimation of the final ablation area was 
shown as an overlay on the anatomic MRI (Fig. 2b). This 
zone was computed using the Arrhenius model for thermal 
tissue ablation [20].
Tumors were only partially ablated, because per patient 
only one ablation was performed to investigate the effect of 
the ablation on the tissue rather than the effectiveness of the 
treatment.
Immediately after ablation, an axial T1-weighted con-
trast-enhanced (T1wCE) sequence was performed (Fig. 2c) 
to assess the size of the ablation. Hereafter, the laser fiber 
and the needle guide were removed. Patients were dis-
charged when voiding was uncomplicated.
Procedure time was determined as from the moment 
the first MRI sequence was started until the last MRI 
sequence was finished, including T2w and DWI, to re-iden-
tify the tumor and T1wCE images to assess ablation zone. 
Three weeks after FLA, patients underwent open radical 
prostatectomy, performed by one of two oncologic urolo-
gists with 25 and 9 years experience.
Histopathology work‑up
The resected prostate specimens were fixed overnight in 
10 % neutral-buffered formaldehyde and coated with ink. 
Transverse whole-mount step sections were created at 4 
mm intervals in a plane parallel to the axial plane used to 
perform the T1-weighted sequence. Apical and basal slices 
were additionally sliced in the sagittal plane and all sec-
tions were embedded in paraffin. Tissue sections of 5 μm 
were stained with hematoxylin-eosin (H&E) (Fig. 2d). 
The presence and extent of necrotic tissue, the surrounding 
perinecrotic zone with reactive changes, and vital tumor 
were annotated on the glass cover with the tissue section. 
In addition, immunostaining for CK8/18, CD31, and Ki67 
was performed to demonstrate the presence of epithelial 
damage, vascular damage, and mitotic activity. The mitotic 
index was determined as the mean count of Ki67-positive 
nuclei in five microscopic fields of 1 mm2 surface area 
(20× objective Zeiss Axioskop). The fields for counting 
were taken in the first 1 mm zone of vital tumor (or pre-
existing prostatic ducts) directly adjacent to the necrotic 
area; at the opposite tumor invasion front; and in the center 
of the tumor more than 2 mm distant from the perinecrotic 
or invasion front areas. For tumor tissue, areas were chosen 
with the same Gleason score and duct density. All measure-
ments were independently performed by two genitourinary 
pathologists with 22 and 27 years experience.
Data analyses
By assuming that the final form of the Arrhenius-based 
damage-estimation zone would be ellipsoid, the length 
and width of the final zone were measured and the abla-
tion volume was calculated. Two experienced prostate MRI 
radiologists with 11 and 3 years experience blinded for 
the final pathology results contoured the ablation zone per 
slice in the post-ablation T1wCE images. The ablation area 
per slice was calculated by the PACS software and multi-
plied with the slice thickness to determine the total abla-
tion volume. Volumes of the necrotic zone annotated on 
the histopathology slices were measured using an in-house 
developed software program. A factor of 1.15 was used to 
correct for tissue shrinkage [21].
Per patient, the volume of the ablated tissue in the 
prostate specimen was compared with the volume of the 
Arrhenius-based ablation zone and the volume of the abla-
tion zone in the T1wCE images by calculating the ratios 
between the volumes. Statistical comparisons were made 
by calculating the Pearson correlation coefficient r and 
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corresponding two-tailed p values with SPSS Statistics 
version 20. P values <0.05 were considered statistically 
significant.
Results
Patients
MRI-guided FLA was safe and feasible to perform and no 
immediate complications were encountered. All patients 
were discharged 1 h after treatment.
Two days after the MRI-guided FLA procedure, one 
patient was hospitalized for 1 week with urosepsis. He was 
treated with intravenous antibiotics and underwent radical 
prostatectomy 3 weeks later. All radical prostatectomies 
were uncomplicated. The surgeons did not report any dif-
ficulties due to the previous laser ablation. All patient and 
procedure characteristics are shown in Table 2.
Histopathological outcomes
The results of both pathologists were in concordance. A 
homogeneous necrotic area surrounded by a reactive peri-
necrotic zone of variable thickness (1–5 mm) was observed 
in all patients. The perinecrotic zone showed pre-existing 
prostatic tissue and tumor tissue with reactive changes, 
such as increased proliferation activity, neovascularisation 
with doubling of the microvessel density, and a variable 
lymphocytic infiltrate. Pre-existing prostate tubuli showed 
reactive epithelial changes, such as increased proliferation 
rate and squamous metaplasia. In the CK8/18, stain tumor 
Fig. 2  Images of a 67-year-
old male with a Gleason 
score 3 + 4 = 7 in his right 
transition zone. a Real-time 
MRI-temperature map acquired 
during FLA. b Anatomical MRI 
of the prostate (delineated in 
blue) with the Arrhenius-based 
damage-estimation zone as 
orange overlay. c Post-ablation 
axial T1-weighted contrast-
enhanced image. The prostate 
is delineated in blue and the 
non-enhancing necrotic tis-
sue in green. d Whole-mount 
H&E stain of the prostate. The 
necrotic tissue is delineated in 
green, the perinecrotic tissue in 
yellow, and vital tumor in blue
Table 2  Patient and procedure characteristics
Patient Age (yr) PSA (ng/mL) Biopsy gleason score Procedure time (min) Ablation time (s) Laser energy (W) Final gleason score
1 66 9.3 3 + 4 84 91 12 3 + 2 (+4)
2 58 8.5 3 + 3 118 91 10 3 + 3
3 67 10.2 4 + 3 100 91 10 3 + 4
4 60 16.2 3 + 4 74 81 15 3 + 4 (+5)
5 70 5.7 3 + 2 59 73 11 3 + 2 (+5)
708 World J Urol (2017) 35:703–711
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tubuli were less resistant to the ablation than pre-existing 
tubuli, which extended further into the necrotic zone or 
perinecrotic zone. However, as indicated by the Ki67 stain, 
the tumor cells showed an increased mitotic index in the 
perinecrotic area (Fig. 3a), adjacent to the ablation area 
(Table 3). An increased mitotic activity was also seen at the 
tumor invasion front (Fig. 3b). The mitotic index was low-
est in the center of the tumor (Fig. 3c).
Volume comparison
All volumetric measurements per individual patient are 
shown in Table 4. The median ratio between the necrotic 
volume of the ablated tissue in the prostate specimen 
(Fig. 2d) and the measured ablation volume on the T1wCE 
MR images (Fig. 2c) was 0.80 (range, 0.40–2.09), and 
showed a significant volume correlation with a Pearson 
correlation coefficient of r = 0.94 (p = 0.018).
The ablation volumes on the damage-estimation maps 
(Fig. 2b) derived from the MRI-temperature maps (Fig. 2a) 
were always larger than the ablation zones in the T1wCE 
MR images and the necrotic volumes in the histopathology 
specimen. The median ratios between those volumes were, 
respectively, 8.77 (range 2.11–21.47) and 5.85 (range 1.39–
25.39), and were poorly correlated; r = 0.26 (p = 0.673) 
and r = 0.33 (p = 0.583).
Fig. 3  Histopathologic Ki67-
stained slides in an axial plane 
through the prostate showing 
mitotic activity represented by 
the brown nuclei. a Perinecrotic 
area, showing increased mitotic 
activity. b Tumor invasion front, 
showing lower mitotic activity 
than in the perinecrotic area. 
c Center area of vital tumor, 
showing hardly any mitotic 
activity
709World J Urol (2017) 35:703–711 
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Discussion
The most important finding of our study was revealed by 
the histopathology results. All prostate specimens showed 
a homogeneous necrotic area surrounded by a perinecrotic 
area of 1–5 mm thickness. However, in this perinecrotic 
area, reactive changes were seen, as for example, neovascu-
larization and an increased mitotic index. These processes 
were also seen in the tumor invasion front were the tumor 
invades in healthy tissue.
Stimulated growth of surviving tumor cells after incom-
plete thermal ablation (cryoablation or radiofrequency 
ablation) was observed earlier in renal tumor cells [22] and 
after incomplete radiofrequency ablation in liver cells [23]. 
Increased tumor cell proliferation was seen up to the end of 
the studies, respectively, 14 and 21 days after ablation, and 
is possibly caused by tissue damage, increased hypoxia, 
increased presence of heat-shock proteins, and inflamma-
tory cells directly adjacent to the ablation area [22]. The 
clinical consequences of this effect remain unclear; in the 
worst-case scenario, it could facilitate tumor outgrowth; 
and in the best case scenario, the effect is only a tempo-
rary reaction on the cellular damage caused by the abla-
tion. More research is needed to gather additional insight 
into these processes. Nevertheless, this highlights the 
importance of complete tumor ablation. To achieve this, 
the lesion size should be clearly visualized for optimal 
treatment planning and targeting and larger safety mar-
gins around the tumor should be employed. Le Nobin et al. 
[24] correlated visible prostate tumor volume on MRI with 
histology and concluded that a 9 mm non-capsular and a 
3 mm capsular treatment margin should be applied to 
ensure complete tumor treatment.
In other ablate-resect studies, performed with MRI-
guided FLA in canine prostates [25], in patients after ultra-
sound-guided FLA [12], or after HIFU [26, 27], increased 
tumor activity was not observed. A possible explanation for 
this difference might be that in all these studies, the total 
tumor was ablated and a less extensive histopathology 
work-up without Ki67 staining was performed.
The damage-estimation zones obviously overestimated 
the final necrotic volume in T1wCE images as well as the 
histopathology specimen, and showed poor volume cor-
relation. The non-enhancing tissue on the post-ablation 
T1wCE MRI gave a better indication of the final histo-
pathologic necrotic volume and showed a significant vol-
ume correlation. One of the reasons for the inconsistency 
between the ablation zones shown on the damage-estima-
tion maps and the obtained ablation volumes in the histo-
pathology specimen is probably due to tissue heterogene-
ity within the prostate. Furthermore, during laser ablation 
tissue properties, as for example, thermal conductivity, 
change due to temperature increase. Other factors which 
could have influenced the MRI-temperature mapping 
and, thus, the Arrhenius-based calculated volumes on the 
damage-estimation maps are the spatial resolution of the 
sequence, patient movement during scanning, and the ina-
bility of measuring temperature changes in extraprostatic 
fat tissue [28].
A study of Oto et al. [5] demonstrated successful MRI-
guided FLA in nine patients. Urinary and sexual function 
did not significantly change afterwards. After 6 months, 
patients underwent MRI-guided biopsy of the ablation 
zone. In 78 %, no tumor was found, and in 22 %, a Gleason 
Score 6 was found. In another study by Lee et al. [16], 23 
patients were treated. Thirteen of them underwent targeted 
biopsy of the ablation zone; only one (7.7 %) showed resid-
ual disease and was re-treated. No changes were seen in 
urinary or sexual functioning 6 months after the procedure. 
Recently, the results of 25 patients were reported by Lepor 
et al. [17]. Three months after treatment, the mean PSA 
decreased of 40 % and post-ablation MRI did not show 
signs of residual or recurrent PCa. Furthermore, targeted 
Table 3  Mitotic index per area
MI mitotic index, BPH benign prostate hyperplasia
Area Mean MI/mm2 (range)
Paranecrotic tumor 99.3 (54–127)
Mid tumor 17.75 (1–58)
Opposite invasion front 41.3 (7–121)
Paranecrotic normal 85.0 (25–215)
Mid normal (BPH) 6.4 (1–21)
Table 4  Volumetric measurements per individual patient
Patient Volume on damage- 
estimation map (cm3)
Volume on T1wCE  
images (cm3)
Volume on histopathology specimen  
corrected with shrinkage factor 1.15 (cm3)
1 3.30 1.00 1.06
2 1.93 0.22 0.00
3 3.65 0.17 0.43
4 2.32 1.10 1.67
5 1.46 0.12 0.06
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biopsy of the ablation zone was performed, and in 96 % of 
the ablation zones, no evidence of residual PCa was found.
This study had several limitations. First, a small sample 
size was used. Because of the large patient burden without 
any personal gain, the IRB committee considered it not 
ethical to treat more than five patients. Second, the volume 
calculations might have been influenced by several factors 
inherent to the difficulty of optimally matching MR images 
with pathology slices. Prostate specimens were sliced in a 
parallel plane used to perform the T1wCE sequence; how-
ever, there might have been small deviations. Furthermore, 
a tissue shrinkage factor of 1.15 was used for all the cases, 
because it was not possible to determine the shrinkage per 
individual prostate. Third, due to the small patient numbers 
and long inclusion period, a learning curve was present, 
especially influencing the procedure time.
Future steps will be to evaluate urinary and sexual func-
tion, quality-of-life, and oncological efficacy of MRI-
guided FLA in patients with low-to-intermediate grade PCa 
on a longer term and large patient population.
In conclusion, this study demonstrated the importance 
of complete tumor ablation with a certain safety margin. 
Furthermore, T1wCE images are more reliable in determin-
ing the final ablation zone than damage-estimation maps 
derived from MRI-temperature maps. Although the initial 
results are promising, longer and thorough follow-up is 
needed to prove long-term outcome of this novel technique.
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